Concepedia

Author

Takuya Tsunoda

The University of TokyoORCID

Also Known As

Kosei Hasegawa, T Tsunoda, T. Tsunoda, TAKUYA TSUNODA, Takashi TSUNODA, Takuya TSUNODA, Takuya Tsunoda, Tsunoda Takuya, Tsunoda, Takuya

289

Publications

4.4K

Citations

39

H-Index

121

Concepts

All Affiliations

The University of TokyoShowa UniversityWakayama Medical UniversityOncoTherapy Science (Japan)Kumamoto University
TT

About

Takuya Tsunoda is an author at The University of Tokyo specializing in medicine, immunology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

51

1.7K

2

Engineering

5

5

110

3

Allergy

4

4

164

4

Natural Sciences

3

3

95

5

Health Sciences

2

2

105

Takuya Tsunoda

×

100

Publications

4K

Citations

38

H-Index

YearCitations

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Andrea L.A. Wong, Ross A. Soo, Daniel S.W. Tan,

Annals of Oncology

2015

166

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

Koji Kono, Hisae Iinuma, Yasunori Akutsu,

Journal of Translational Medicine

2012

142

Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer

Koji Kono, Yoshiki Mizukami, Yataro Daigo,

Cancer Science

2009

136

Identification of human leukocyte antigen‐A24‐restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy

Takako Suda, Takuya Tsunoda, Yataro Daigo,

Cancer Science

2007

120

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

Motoki Miyazawa, R. Ohsawa, Takuya Tsunoda,

Cancer Science

2009

117

Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.

Saori Nakahara, Takuya Tsunoda, Toshiyuki Baba,

PubMed

2003

111

Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers

Katsunori Imai, Shinya Hirata, Atsushi Irie,

Clinical Cancer Research

2008

108

Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2

Satoshi Wada, Takuya Tsunoda, Toshiyuki Baba,

Cancer Research

2005

101

Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Hisae Iinuma, Ryoji Fukushima, Tsuyoshi Inaba,

Journal of Translational Medicine

2014

93

HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL

Michiko Harao, Shinya Hirata, Atsushi Irie,

International Journal of Cancer

2008

92

Page 1